464 related articles for article (PubMed ID: 30785826)
1. West German Study PlanB Trial: Adjuvant Four Cycles of Epirubicin and Cyclophosphamide Plus Docetaxel Versus Six Cycles of Docetaxel and Cyclophosphamide in HER2-Negative Early Breast Cancer.
Nitz U; Gluz O; Clemens M; Malter W; Reimer T; Nuding B; Aktas B; Stefek A; Pollmanns A; Lorenz-Salehi F; Uleer C; Krabisch P; Kuemmel S; Liedtke C; Shak S; Wuerstlein R; Christgen M; Kates RE; Kreipe HH; Harbeck N;
J Clin Oncol; 2019 Apr; 37(10):799-808. PubMed ID: 30785826
[TBL] [Abstract][Full Text] [Related]
2. Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trial.
Nitz U; Gluz O; Christgen M; Kates RE; Clemens M; Malter W; Nuding B; Aktas B; Kuemmel S; Reimer T; Stefek A; Lorenz-Salehi F; Krabisch P; Just M; Augustin D; Liedtke C; Chao C; Shak S; Wuerstlein R; Kreipe HH; Harbeck N
Breast Cancer Res Treat; 2017 Oct; 165(3):573-583. PubMed ID: 28664507
[TBL] [Abstract][Full Text] [Related]
3. Epirubicin Plus Cyclophosphamide Followed by Docetaxel Versus Epirubicin Plus Docetaxel Followed by Capecitabine As Adjuvant Therapy for Node-Positive Early Breast Cancer: Results From the GEICAM/2003-10 Study.
Martín M; Ruiz Simón A; Ruiz Borrego M; Ribelles N; Rodríguez-Lescure Á; Muñoz-Mateu M; González S; Margelí Vila M; Barnadas A; Ramos M; Del Barco Berron S; Jara C; Calvo L; Martínez-Jáñez N; Mendiola Fernández C; Rodríguez CA; Martínez de Dueñas E; Andrés R; Plazaola A; de la Haba-Rodríguez J; López-Vega JM; Adrover E; Ballesteros AI; Santaballa A; Sánchez-Rovira P; Baena-Cañada JM; Casas M; del Carmen Cámara M; Carrasco EM; Lluch A
J Clin Oncol; 2015 Nov; 33(32):3788-95. PubMed ID: 26416999
[TBL] [Abstract][Full Text] [Related]
4. Dose-dense FEC followed by docetaxel versus docetaxel plus cyclophosphamide as adjuvant chemotherapy in women with HER2-negative, axillary lymph node-positive early breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG).
Mavroudis D; Matikas A; Malamos N; Papakotoulas P; Kakolyris S; Boukovinas I; Athanasiadis A; Kentepozidis N; Ziras N; Katsaounis P; Saloustros E; Georgoulias V;
Ann Oncol; 2016 Oct; 27(10):1873-8. PubMed ID: 27502729
[TBL] [Abstract][Full Text] [Related]
5. [Docetaxel plus carboplatin versus EC-T as adjuvant chemotherapy for triple-negative breast cancer: safety data from a phase III randomized open-label trial].
Yuan P; Xu BH; Wang JY; Ma F; Li Q; Zhang P; Fan Y; Li Q; Wang WM
Zhonghua Zhong Liu Za Zhi; 2012 Jun; 34(6):465-8. PubMed ID: 22967451
[TBL] [Abstract][Full Text] [Related]
6. Effect of Adjuvant Trastuzumab for a Duration of 9 Weeks vs 1 Year With Concomitant Chemotherapy for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: The SOLD Randomized Clinical Trial.
Joensuu H; Fraser J; Wildiers H; Huovinen R; Auvinen P; Utriainen M; Nyandoto P; Villman KK; Halonen P; Granstam-Björneklett H; Lundgren L; Sailas L; Turpeenniemi-Hujanen T; Tanner M; Yachnin J; Ritchie D; Johansson O; Huttunen T; Neven P; Canney P; Harvey VJ; Kellokumpu-Lehtinen PL; Lindman H
JAMA Oncol; 2018 Sep; 4(9):1199-1206. PubMed ID: 29852043
[TBL] [Abstract][Full Text] [Related]
7. A randomized study comparing docetaxel/cyclophosphamide (TC), 5-fluorouracil/epirubicin/cyclophosphamide (FEC) followed by TC, and TC followed by FEC for patients with hormone receptor-positive HER2-negative primary breast cancer.
Ishiguro H; Masuda N; Sato N; Higaki K; Morimoto T; Yanagita Y; Mizutani M; Ohtani S; Kaneko K; Fujisawa T; Takahashi M; Kadoya T; Matsunami N; Yamamoto Y; Ohno S; Takano T; Morita S; Tanaka-Mizuno S; Toi M
Breast Cancer Res Treat; 2020 Apr; 180(3):715-724. PubMed ID: 32170634
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant Capecitabine With Docetaxel and Cyclophosphamide Plus Epirubicin for Triple-Negative Breast Cancer (CBCSG010): An Open-Label, Randomized, Multicenter, Phase III Trial.
Li J; Yu K; Pang D; Wang C; Jiang J; Yang S; Liu Y; Fu P; Sheng Y; Zhang G; Cao Y; He Q; Cui S; Wang X; Ren G; Li X; Yu S; Liu P; Qu X; Tang J; Wang O; Fan Z; Jiang G; Zhang J; Wang J; Zhang H; Wang S; Zhang J; Jin F; Rao N; Ma B; He P; Xu B; Zhuang Z; Wang J; Sun Q; Guo X; Mo M; Shao Z;
J Clin Oncol; 2020 Jun; 38(16):1774-1784. PubMed ID: 32275467
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant Cyclophosphamide and Docetaxel With or Without Epirubicin for Early TOP2A-Normal Breast Cancer: DBCG 07-READ, an Open-Label, Phase III, Randomized Trial.
Ejlertsen B; Tuxen MK; Jakobsen EH; Jensen MB; Knoop AS; Højris I; Ewertz M; Balslev E; Danø H; Vestlev PM; Kenholm J; Nielsen DL; Bechmann T; Andersson M; Cold S; Nielsen HM; Maae E; Carlsen D; Mouridsen HT
J Clin Oncol; 2017 Aug; 35(23):2639-2646. PubMed ID: 28661759
[TBL] [Abstract][Full Text] [Related]
10. Superior outcome after neoadjuvant chemotherapy with docetaxel, anthracycline, and cyclophosphamide versus docetaxel plus cyclophosphamide: results from the NATT trial in triple negative or HER2 positive breast cancer.
Chen X; Ye G; Zhang C; Li X; Chen Y; Xie X; Zheng H; Cao Y; Wu K; Ni D; Tang J; Wei Z; Shen K
Breast Cancer Res Treat; 2013 Dec; 142(3):549-58. PubMed ID: 24292815
[TBL] [Abstract][Full Text] [Related]
11. Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study.
von Minckwitz G; Rezai M; Loibl S; Fasching PA; Huober J; Tesch H; Bauerfeind I; Hilfrich J; Eidtmann H; Gerber B; Hanusch C; Kühn T; du Bois A; Blohmer JU; Thomssen C; Dan Costa S; Jackisch C; Kaufmann M; Mehta K; Untch M
J Clin Oncol; 2010 Apr; 28(12):2015-23. PubMed ID: 20308671
[TBL] [Abstract][Full Text] [Related]
12. A multicenter phase III prospective randomized trial of high-dose epirubicin in combination with cyclophosphamide (EC) versus docetaxel followed by EC in node-positive breast cancer. GOIM (Gruppo Oncologico Italia Meridionale) 9902 study.
Vici P; Brandi M; Giotta F; Foggi P; Schittulli F; Di Lauro L; Gebbia N; Massidda B; Filippelli G; Giannarelli D; Di Benedetto A; Mottolese M; Colucci G; Lopez M
Ann Oncol; 2012 May; 23(5):1121-1129. PubMed ID: 21965475
[TBL] [Abstract][Full Text] [Related]
13. UCBG 2-04: Long-term results of the PACS 04 trial evaluating adjuvant epirubicin plus docetaxel in node-positive breast cancer and trastuzumab in the human epidermal growth factor receptor 2-positive subgroup.
D'Hondt V; Canon JL; Roca L; Levy C; Pierga JY; Le Du F; Campone M; Desmoulins I; Goncalves A; Debled M; Rios M; Ferrero JM; Serin D; Hardy-Bessard AC; Piot G; Brain E; Dohollou N; Orfeuvre H; Lemonnier J; Roché H; Delaloge S; Dalenc F
Eur J Cancer; 2019 Nov; 122():91-100. PubMed ID: 31634648
[TBL] [Abstract][Full Text] [Related]
14. Effect of Tailored Dose-Dense Chemotherapy vs Standard 3-Weekly Adjuvant Chemotherapy on Recurrence-Free Survival Among Women With High-Risk Early Breast Cancer: A Randomized Clinical Trial.
Foukakis T; von Minckwitz G; Bengtsson NO; Brandberg Y; Wallberg B; Fornander T; Mlineritsch B; Schmatloch S; Singer CF; Steger G; Egle D; Karlsson E; Carlsson L; Loibl S; Untch M; Hellström M; Johansson H; Anderson H; Malmström P; Gnant M; Greil R; Möbus V; Bergh J;
JAMA; 2016 Nov; 316(18):1888-1896. PubMed ID: 27825007
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial.
Joensuu H; Kellokumpu-Lehtinen PL; Huovinen R; Jukkola-Vuorinen A; Tanner M; Kokko R; Ahlgren J; Auvinen P; Paija O; Helle L; Villman K; Nyandoto P; Nilsson G; Pajunen M; Asola R; Poikonen P; Leinonen M; Kataja V; Bono P; Lindman H
J Clin Oncol; 2012 Jan; 30(1):11-8. PubMed ID: 22105826
[TBL] [Abstract][Full Text] [Related]
16. Addition of gemcitabine to paclitaxel, epirubicin, and cyclophosphamide adjuvant chemotherapy for women with early-stage breast cancer (tAnGo): final 10-year follow-up of an open-label, randomised, phase 3 trial.
Earl HM; Hiller L; Howard HC; Dunn JA; Young J; Bowden SJ; McDermaid M; Waterhouse AK; Wilson G; Agrawal R; O'Reilly S; Bowman A; Ritchie DM; Goodman A; Hickish T; McAdam K; Cameron D; Dodwell D; Rea DW; Caldas C; Provenzano E; Abraham JE; Canney P; Crown JP; Kennedy MJ; Coleman R; Leonard RC; Carmichael JA; Wardley AM; Poole CJ;
Lancet Oncol; 2017 Jun; 18(6):755-769. PubMed ID: 28479233
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial.
Francis P; Crown J; Di Leo A; Buyse M; Balil A; Andersson M; Nordenskjöld B; Lang I; Jakesz R; Vorobiof D; Gutiérrez J; van Hazel G; Dolci S; Jamin S; Bendahmane B; Gelber RD; Goldhirsch A; Castiglione-Gertsch M; Piccart-Gebhart M;
J Natl Cancer Inst; 2008 Jan; 100(2):121-33. PubMed ID: 18182617
[TBL] [Abstract][Full Text] [Related]
18. Feasibility and cardiac safety of trastuzumab emtansine after anthracycline-based chemotherapy as (neo)adjuvant therapy for human epidermal growth factor receptor 2-positive early-stage breast cancer.
Krop IE; Suter TM; Dang CT; Dirix L; Romieu G; Zamagni C; Citron ML; Campone M; Xu N; Smitt M; Gianni L
J Clin Oncol; 2015 Apr; 33(10):1136-42. PubMed ID: 25713436
[TBL] [Abstract][Full Text] [Related]
19. Optimal duration of adjuvant chemotherapy for high-risk node-negative (N-) breast cancer patients: 6-year results of the prospective randomised multicentre phase III UNICANCER-PACS 05 trial (UCBG-0106).
Kerbrat P; Desmoulins I; Roca L; Levy C; Lortholary A; Marre A; Delva R; Rios M; Viens P; Brain É; Serin D; Edel M; Debled M; Campone M; Mourret-Reynier MA; Bachelot T; Foucher-Goudier MJ; Asselain B; Lemonnier J; Martin AL; Roché H
Eur J Cancer; 2017 Jul; 79():166-175. PubMed ID: 28501763
[TBL] [Abstract][Full Text] [Related]
20. Randomized, phase III trial of sequential epirubicin and docetaxel versus epirubicin alone in postmenopausal patients with node-positive breast cancer.
Coombes RC; Bliss JM; Espie M; Erdkamp F; Wals J; Tres A; Marty M; Coleman RE; Tubiana-Mathieu N; den Boer MO; Wardley A; Kilburn LS; Cooper D; Thomas MW; Reise JA; Wilkinson K; Hupperets P
J Clin Oncol; 2011 Aug; 29(24):3247-54. PubMed ID: 21768453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
